Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New brain scan sheds light on Parkinson's and aging

NCT ID NCT07569120

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jul 10, 2026 · Updated 4 times

Summary

This study uses advanced PET/MRI scanning to examine the noradrenaline system in the brains of 165 healthy adults and people with Parkinson's disease. Participants receive a radioactive tracer that binds to specific receptors, allowing researchers to see how this system changes with age and disease. The goal is to link these brain changes to thinking, memory, and movement abilities.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
[11C]ORM-13070 (a radioactive tracer for PET scans)
What this could lead to
If successful, this could reveal how the noradrenaline system changes with age and in Parkinson's, potentially guiding future treatments for cognitive and motor symptoms.
What could go wrong
This is an observational imaging study, not a treatment trial. It is early-stage and may not directly lead to new therapies. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 165 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Sep 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 80 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria for the healthy controls: * Age between 20 years and 80 years * Weight between 40kg and 100kg * Without neurologic or psychiatric history * Without head trauma history including loss of consciousness superior to 30 minutes. * With highly effective contraception for women of childbearing age * Affiliated to a social security or similar scheme * Not subject to any legal protection measures * Participant must have signed an informed consent document Inclusion Criteria for the patients with Parkinson's disease: * Age between 40 years and 80 years * Weight between 40kg and 100kg * With an idiopathic Parkinson's disease (Dopa-sensitive) * Without head trauma history including loss of consciousness superior to 30 minutes. * Without associated neurological pathology * With highly effective contraception for women of childbearing age * Affiliated to a social security or similar scheme * Not subject to any legal protection measures * Participant must have signed an informed consent document Exclusion Criteria for all participants : * Subject receiving (or having received in the last month) somatic medication with cerebral or psychological effects (e.g., antihistamines), see list in Appendix1 * Subjects with a current or past dependence on alcohol or any other addictive substance according to DSM-IV-TR criteria, with the exception of nicotine and caffeine; - * Subjects already participating in another biomedical research project or who have participated in a study using ionizing radiation within the past year; * Pregnant woman parturient or breastfeeding * MRI contraindications (: people using pacemaker or insulin pumps, with implanted or embedded metal objects in the head or body, claustrophobic, with neurosensory stimulators or implantable defibrillators, with cochlear implants, with ferromagnetic foreign bodies in the eye or brain close to nerve structures, agitation of the subject (uncooperative or agitated subjects), ventriculoperitoneal neurosurgical shunt valves, dental appliances) * Subject with a contraindication to PET scans at the ORM: hypersensitivity to the active substance or to any of the excipients (sodium chloride) * Subjects who are unable to understand or complete the study (language barrier, obvious lack of motivation, etc.) as judged by the investigator. * Subjects who do not agree to be informed in the event of an incidental finding of an abnormality on MRI or during neuropsychological assessment. * Persons deprived of their liberty by judicial or administrative decision. * Persons receiving psychiatric care. * Persons admitted to a health or social care facility for purposes other than research.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy aging and Parkinson's disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hôpital Neurologique Pierre Wertheimer - Service de Neurologie

    RECRUITING

    Bron, 69500, France